Memantine for alcohol dependence: An open-label pilot study

Addictive Disorders and their Treatment

Volumn 6, Issue 2, 2007, Pages 77-83

  Arias, Albert J ^a   Feinn, Richard ^c   Covault, Jonathan ^a   Kranzler, Henry R ^a,b  

^a UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alcohol dependence; Glutamate; Memantine; NMDA antagonist

Indexed keywords

MEMANTINE;

ADULT; ALCOHOL ABSTINENCE; ALCOHOLISM; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COPING BEHAVIOR; DIZZINESS; DOSE RESPONSE; DRINKING BEHAVIOR; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; LIBIDO; MALE; OPEN STUDY; OUTCOME ASSESSMENT; PILOT STUDY; PRIORITY JOURNAL; SEXUAL AROUSAL; SIDE EFFECT; SLEEP DISORDER;

EID: 34249908640     PISSN: 15315754     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.adt.0000210724.41187.4a     Document Type: Article

References (17)

1. Möbius HJ. Memantine: update on the current evidence. Int J Geriatr Psychiatry. 2003;18(Suppl 1), S47-S54.
2. Parsons CG, Danysz W, Quack G. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist - a review of preclinical data. Neuropharmacology. 1999;38:735-767.
3. Hölter SM, Danysz W, Spanagel R. Evidence for alcohol anti-craving properties of memantine. Eur J Pharmacol. 1996;314:R1-R2.
4. Hölter SM, Danysz W, Spanagel R. Novel uncompetitive N-methyl-D-aspartate (NMDA)-receptor antagonist MRZ 2/579 suppresses ethanol intake in long-term ethanol-experienced rats and generalizes to ethanol cue in drug discrimination procedure. J Pharmacol Expl Ther. 2000;292:545-552.
5. Kotlińska J. NMDA antagonists inhibit the development of ethanol dependence in rats. Pol J Pharmacol. 2001;53:47-50.
6. Bisaga A, Evans SM. Acute effects of memantine in combination with alcohol in moderate drinkers. Psychopharmacology (Berlin). 2004;172:16-24.
7. Littleton J, Zieglegansberger W. Pharmacological mechanisms of naltrexone and acamprosate in the prevention of relapse in alcohol dependence. Am J Addict. 2003;12(suppl 1):S3-S11.
8. Anton RF, Swift RM. Current pharmacotherapies of alcoholism: a U.S. Perspective. Am J Addict. 2003;12(suppl 1):S53-S68.
9. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
10. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM-IV Axis I Disorders-Patient Edition (SCID-I/P, Version 2.0), Biometrics Research Department, New York State Psychiatric Institute: New York; 1995.
11. Beck AT, Ward CH, Mendelson M, et al. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4:461-471.
12. Bohn MJ, Krahn DD, Staehler BA. Development and initial validation of a measure of drinking urges in abstinent alcoholics. Alcohol Clin Exp Res. 1995;19:600-606.
13. Sobell L, Sobell M. Timeline follow-back: a technique for assessing self-reported alcohol consumption. In: Litten R, Allen J, eds. Measuring Alcohol Consumption. Clifton, NJ: Human Press; 1992.
14. The Drinker Inventory of Consequences (DrInC). NIAAA Project MATCH Monograph Series, Vol. 4. NIH Publ. No. 95-3911, 1995.
15. Feinn R, Tennen H, Kranzler HR. Psychometric properties of the SIP in measuring recent alcohol-related problems. Alcohol Clin Exp Res. 2003;27:1436-1441.
16. Brown SA, Schuckit MA. Changes in depression among abstinent alcoholics. J Stud Alcohol. 1988;49:412-417.
17. Dorus W, Kennedy J, Gibbons RD, et al. Symptoms and diagnosis of depression in alcoholics. Alcohol Clin Exp Res. 1987;11:150-154.